Suppression of malignancy utilizing ribonucleotide reductase R1
AssigneeGenesense Technologies Inc.
InventorsJim A. Wright, Aiping H. Young
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of modulating the malignant properties of a cell in a human or other mammal by contacting a neoplastic cell with a growth modulating amount of an expressible nucleic acid sequence for ribonucleotide reductase R1 of the mammal. The present invention also provides and uses a growth modulating amount of the ribonucleotide reductase R1 protein or biologically active peptide to modulate the malignant properties of a cell in a human or other mammal. The method provides for a generally elevated expression of the R1 component of mammalian ribonucleotide reductase. The expressible nucleic acid sequence can be in the form of a vector for gene therapy.
Claims10
A method for inhibiting growth of a neoplastic cell in a mammal, the method comprising the step of increasing the expression of ribonucleotide reductase R1 by administering directly into said neoplastic cell a nucleic acid molecule encoding a ribonucleotide reductase R1, whereby the expression of said ribonucleotide reductase R1 is increased and inhibits the growth of said neoplastic cell.
A method for inhibiting the malignant growth of a neoplastic cell in a mammal, the method comprising the step of increasing the expression of ribonucleotide reductase R1 by administering directly into said neoplastic cell a nucleic acid molecule encoding a ribonucleotide reductase R1, whereby the expression of said ribonucleotide reductase R1 is increased and inhibits the malignant growth of said neoplastic cell.
Dependencies are inferred from the claim text.